AbbVie Cash on Hand 2010-2020 | ABBV

AbbVie cash on hand from 2010 to 2020. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • AbbVie cash on hand for the quarter ending June 30, 2020 was $41.142B, a 686.95% increase year-over-year.
  • AbbVie cash on hand for 2019 was $39.924B, a 395.27% increase from 2018.
  • AbbVie cash on hand for 2018 was $8.061B, a 17.65% decline from 2017.
  • AbbVie cash on hand for 2017 was $9.789B, a 52.41% increase from 2016.
AbbVie Annual Cash on Hand
(Millions of US $)
2019 $39,924
2018 $8,061
2017 $9,789
2016 $6,423
2015 $8,407
2014 $8,374
2013 $9,895
2012 $7,976
2011 $653
2010 $11
2009 $
AbbVie Quarterly Cash on Hand
(Millions of US $)
2020-03-31 $41,142
2019-12-31 $39,924
2019-09-30 $10,648
2019-06-30 $5,416
2019-03-31 $5,228
2018-12-31 $8,061
2018-09-30 $8,785
2018-06-30 $3,743
2018-03-31 $9,474
2017-12-31 $9,789
2017-09-30 $9,554
2017-06-30 $7,205
2017-03-31 $6,248
2016-12-31 $6,423
2016-09-30 $7,950
2016-06-30 $8,002
2016-03-31 $8,600
2015-12-31 $8,407
2015-09-30 $9,249
2015-06-30 $8,279
2015-03-31 $7,924
2014-12-31 $8,374
2014-09-30 $10,323
2014-06-30 $10,246
2014-03-31 $9,100
2013-12-31 $9,895
2013-09-30 $9,596
2013-06-30 $8,754
2013-03-31 $7,479
2012-12-31 $7,976
2012-09-30 $4,586
2012-06-30 $75
2012-03-31 $43
2011-12-31 $653
2011-09-30
2011-06-30
2011-03-31
2010-12-31 $11
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $163.371B $33.266B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.473B 18.51
Roche Holding AG (RHHBY) Switzerland $297.430B 0.00
Pfizer (PFE) United States $212.584B 13.29
Merck (MRK) United States $204.995B 14.63
Novartis AG (NVS) Switzerland $190.900B 14.84
Novo Nordisk (NVO) Denmark $149.977B 24.98
AstraZeneca (AZN) United Kingdom $147.516B 28.68
Eli Lilly (LLY) United States $146.225B 22.32
Sanofi (SNY) $128.963B 15.33
GlaxoSmithKline (GSK) United Kingdom $102.774B 13.48
Bayer (BAYRY) Germany $61.996B 8.94
H Lundbeck (HLUYY) Denmark $7.279B 12.65
Innoviva (INVA) United States $1.361B 6.52